MedPath

惠升生物制药股份有限公司

Ownership
-
Established
2019-05-17
Employees
-
Market Cap
-
Website
http://www.huishengpharm.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

24

NMPA:24

Drug Approvals

Dapagliflozin Tablets

Product Name
达格列净片
Approval Number
国药准字H20253933
Approval Date
Apr 15, 2025
NMPA

Dapagliflozin Tablets

Product Name
达格列净片
Approval Number
国药准字H20253934
Approval Date
Apr 15, 2025
NMPA

Empagliflozin Tablets

Product Name
恩格列净片
Approval Number
国药准字H20249837
Approval Date
Dec 25, 2024
NMPA

Linagliptin Tablets

Product Name
利格列汀片
Approval Number
国药准字H20249802
Approval Date
Dec 25, 2024
NMPA

Empagliflozin Tablets

Product Name
恩格列净片
Approval Number
国药准字H20249836
Approval Date
Dec 25, 2024
NMPA

Epalrestat Tablets

Product Name
依帕司他片
Approval Number
国药准字H20249380
Approval Date
Nov 15, 2024
NMPA

Insulin Degludec Injection

Product Name
惠优达
Approval Number
国药准字S20240033
Approval Date
Aug 5, 2024
NMPA

Insulin Degludec Injection

Product Name
惠优达
Approval Number
国药准字S20240032
Approval Date
Aug 5, 2024
NMPA

Insulin Degludec and Insulin Aspart Injection

Product Name
惠优加
Approval Number
国药准字S20240031
Approval Date
Jul 30, 2024
NMPA

Insulin Degludec and Insulin Aspart Injection

Product Name
惠优加
Approval Number
国药准字S20240030
Approval Date
Jul 30, 2024
NMPA
  • Prev
  • 1
  • 2
  • 3
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.